DYAI
NASDAQDyadic International Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
Price$0.75-0.13 (-15.00%)
2026-01-282026-05-01
News · 26 weeks34-40%
2025-11-092026-05-03
Mix1790d
- Other7(41%)
- SEC Filings7(41%)
- Earnings3(18%)
Latest news
25 items- SECSEC Form PRE 14A filed by Dyadic International Inc.PRE 14A - DYADIC INTERNATIONAL INC (0001213809) (Filer)
- SECAmendment: SEC Form 10-K/A filed by Dyadic International Inc.10-K/A - DYADIC INTERNATIONAL INC (0001213809) (Filer)
- PRDyadic to Report Q1 2026 Financial Results and Host Conference Call on Wednesday May 13, 2026JUPITER, Fla., April 29, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced that it will report its financial results for the quarter ended March 31, 2026 and host a corporate update conference call on Wednesday, May 13, 2026. Conference Call Information Date: Wednesday, May 13, 2026 Time: 5:00 p.m. Eastern Tim
- SECSEC Form 8-K filed by Dyadic International Inc.8-K - DYADIC INTERNATIONAL INC (0001213809) (Filer)
- PRDyadic Announces 2025 Financial Results and Highlights Recent Company ProgressCommercial launch of AlbuFree™ DX recombinant human albumin by Proliant Health & Biologicals using Dyadic's production platform, with Dyadic eligible to receive a share of profits from product salesExpanded strategic collaboration with Fermbox Bio, including the launch of animal-origin-free recombinant DNase I (RNase-free) as the first commercialized product under the expanded partnershipSigned an OEM distribution agreement with IBT Bioservices to commercialize Dyadic's recombinant DNase I and transferrin for research and cell culture applications through IBT's global distribution channelsEntered a development and commercialization agreement with BRIG Bio to produce animal-free bovine alpha-
- SECDyadic International Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - DYADIC INTERNATIONAL INC (0001213809) (Filer)
- SECSEC Form 10-K filed by Dyadic International Inc.10-K - DYADIC INTERNATIONAL INC (0001213809) (Filer)
- PRDyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT BioservicesJUPITER, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life science, food and nutrition, and bioindustrial applications today announced that it has entered into an original equipment manufacturer ("OEM") distribution agreement with Integrated Biotherapeutics, LLC, d/b/a IBT Bioservices ("IBT"), a life sciences reagent manufacturer and distributor serving global research markets. Through this collaboration, Dyadic-produced recombinant protein products will be commercialized through IBT's established sales ch
- PRLife Sciences Virtual Investor Forum Presentations Now Available for Online ViewingNEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that presentations from the Life Sciences Virtual Investor Forum, held March 11th – 12th, are now available for on-demand viewing. The forum featured CEO chats and company presentations from leadership teams representing innovative companies across the biotechnology, medical device, and pharmaceutical sectors, offering investors insights into emerging technologies, strategic initiatives, and growth opportunities within the life sciences industry. REGISTER AND VIEW PRESENTATIONS HERE The presentations will be available 24/7 for 90 days. Investors,
- PRDyadic to Report 2025 Full Year Financial Results and Host Conference Call on Wednesday, March 25, 2026JUPITER, Fla., March 11, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced that it will report its financial results for the year ended December 31, 2025 and host a corporate update conference call on Wednesday, March 25, 2026. Conference Call Information Date: Wednesday, March 25, 2026 Time: 5:00 p.m. Eastern
- PRLife Sciences Virtual Investor Forum Agenda Announced for March 11th & 12thNEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place March 11–12, 2026. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE Investors are encouraged to pre-register and run the online system check to expedite participation and receive event updates. Participation is free, and attendees may watch live company presentations and schedule one-on-one meetings with management teams. Schedule 1x1 meetings here "We are delighted to highlight today's innovators from the Life Science
- SECSEC Form 8-K filed by Dyadic International Inc.8-K - DYADIC INTERNATIONAL INC (0001213809) (Filer)
- SECSEC Form 424B5 filed by Dyadic International Inc.424B5 - DYADIC INTERNATIONAL INC (0001213809) (Filer)
- PRDyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)JUPITER, Fla. and BENGALURU, India, March 04, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life science, food and nutrition, and bio-industrial uses, and Fermbox Bio ("Fermbox"), a biotech research and manufacturing company developing sustainable bio-based products through precision fermentation and advanced biotechnology tools, today announced the commercial launch of animal-origin-free Recombinant DNase I (RNase-free). This represents the first commercialized product under the companies expanded collaboration announced
- PRDyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development MilestoneJUPITER, Fla. and COPENHAGEN, Denmark, March 02, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life science, food and nutrition, and bio-industrial uses, and Inzymes ApS ("Inzymes"), a Denmark-based enzyme company specializing in the development, scale-up, and commercialization of enzymes for sustainable food and beverage applications, today announced the planned 2026 commercialization of recombinant non-animal bovine chymosin, a key enzyme used in cheese production and dairy processing, following the successful completion
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Dyadic International Inc.SCHEDULE 13G/A - DYADIC INTERNATIONAL INC (0001213809) (Subject)
- PRDyadic Applied BioSolutions and Proliant Health & Biologicals Announce Commercial Launch of Recombinant Human AlbuminJUPITER, Fla. and ANKENY, Iowa, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life science, food and nutrition, and bio-industrial uses, and Proliant Health & Biologicals ("Proliant"), a leading global producer of albumin and other purified proteins for life science, nutrition, and diagnostic applications, today announced the commercial launch of AlbuFree™ DX, a recombinant human albumin (rHA) product produced using Dyadic's proprietary filamentous fungal expression technology. The launch of AlbuFree™ DX undersco
- INSIDERVP of Research and Bus. Dvlpmt Tchelet Ronen was granted 18,064 shares, increasing direct ownership by 55% to 50,897 units (SEC Form 4)4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)
- INSIDERChief Financial Officer Rawson Ping Wang was granted 29,158 shares, increasing direct ownership by 21% to 170,151 units (SEC Form 4)4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)
- INSIDERDirector Lucy Patrick K. converted options into 21,552 shares, increasing direct ownership by 42% to 72,311 units (SEC Form 4)4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)
- INSIDERDirector Kaye Jack converted options into 21,552 shares, increasing direct ownership by 36% to 81,201 units (SEC Form 4)4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)
- INSIDERDirector Herbst Seth converted options into 21,552 shares, increasing direct ownership by 12% to 202,311 units (SEC Form 4)4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)
- INSIDERPresident & COO Hazelton Joseph P was granted 36,418 shares, increasing direct ownership by 23% to 191,758 units (SEC Form 4)4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)
- INSIDERCEO Emalfarb Mark A was granted 102,609 shares, increasing direct ownership by 2% to 4,832,667 units (SEC Form 4)4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)
- INSIDERSEC Form 4 filed by CEO Emalfarb Mark A4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)
DYAI FAQ
6 questionsWhat does Dyadic International Inc. do?
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-S-RBD antigen...Where does DYAI stock trade?
Dyadic International Inc. (DYAI) is listed on NASDAQ.What sector and industry is DYAI in?
Dyadic International Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What are analysts saying about DYAI?
Dyadic International Inc. has had 4 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $300.00 price target on 2025-10-23. Recent price targets range from $300.00 to $700.00.What companies are similar to DYAI?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare DYAI side-by-side with any of them on Quantisnow.How can I track DYAI on Quantisnow?
Quantisnow aggregates Dyadic International Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DYAI to receive live email and push alerts on every new disclosure.